Celcuity

$9.89
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.54 (+5.78%) Today

$0.00 (0.00%) As of 10:00 PM UTC after-hours

Why Robinhood?

You can buy or sell Celcuity and other stocks, options, and ETFs commission-free!

About CELC

Celcuity Inc. Common Stock, also called Celcuity, is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN. The listed name for CELC is Celcuity Inc. Common Stock.

CEO

Brian F. Sullivan

Employees

Headquarters

Minneapolis, Minnesota

Founded

2012

Market Cap

101.84M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

14.63K

High Today

$9.89

Low Today

$9.22

Open Price

$9.22

Volume

18.80K

52 Week High

$12.70

52 Week Low

$4.03

Collections

CELC Earnings

-$0.25

-$0.17

-$0.08

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 11, After Hours